Intratumor heterogeneity in evolutionary models of tumor progression

Genetics

Volumn 188, Issue 2, 2011, Pages 461-477

  Durrett, Rick ^a   Foo, Jasmine ^b   Leder, Kevin ^b   Mayberry, John ^c   Michor, Franziska ^b  

^a DUKE UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARCINOGENESIS; CELL HETEROGENEITY; CELL POPULATION; CONTROLLED STUDY; EPIGENETICS; GENE MUTATION; GENETIC TRAIT; GENETIC VARIABILITY; HERITABILITY; HOMOZYGOTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

ALGORITHMS; CELL LINEAGE; CLONE CELLS; DISEASE PROGRESSION; GENETIC HETEROGENEITY; HUMANS; MODELS, GENETIC; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 79953300544     PISSN: 00166731     EISSN: 00166731     Source Type: Journal    
DOI: 10.1534/genetics.110.125724     Document Type: Article

References (49)

1. Beerenwinkel, N., T. Antal, D. Dingli, A. Traulsen, K.W. Kinzler et al., 2007 Genetic progression and the waiting time to cancer. PLoS Comput. Biol. 3: e225.
2. Bozic, I., T. Antal, H. Ohtsuki, H. Carter, D. Kim et al., 2010 Accumulation of driver and passenger mutations during tumor progression. Proc. Natl. Acad. Sci. USA 107: 18545-18550.
3. Campbell, L. L., and K. Polyak, 2007 Breast tumor heterogeneity: Cancer stem cells or clonal evolution? Cell Cycle 6: 2332-2338.
4. Coldman, A. J., and J. H. Goldie, 1985 Role of mathematical modeling in protocol formulation in cancer chemotherapy. Cancer Treat. Rep. 69: 1041-1048.
5. Coldman, A. J., and J. H. Goldie, 1986 A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull. Math. Biol. 48: 279-292.
6. Darling, D. A., 1952 The role of the maximum term in the sum of independent random variables. Trans. Am. Math. Soc. 72: 85-107.
7. Dick, J. E., 2008 Stem cell concepts renew cancer research. Blood 112: 4793-4807.
8. Durrett, R., 2005 Probability: Theory and Examples. Brooks Cole-Thomson Learning, Belmont, CA.
9. Durrett, R., and S. Moseley, 2010 Evolution of resistance and progression to disease during clonal expansion of cancer. Theor. Popul. Biol. 77: 42-48.
10. Durrett, R., J. Foo, K. Leder, J. Mayberry and F. Michor, 2010 Evolutionary dynamics of tumor progression with random fitness values. Theor. Popul. Biol. 78: 54-66.
11. Durrett, R., and J. Mayberry, 2011 Traveling waves of selective sweeps. Ann. Appl. Probab. 21: 699-744.
12. Durrett, R., and S. Moseley, 2010 Evolution of resistance and progression to disease during clonal expansion of cancer. Theor. Popul. Biol. 77: 42-48.
13. Durrett, R., J. Foo, K. Leder, J. Mayberry and F. Michor, 2010 Evolutionary dynamics of tumor progression with random fitness values. Theor. Popul. Biol. 78: 54-66.
14. Fidler, I. J., 1978 Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 38: 2651-2660.
15. Fidler, I. J., and I. R. Hart, 1982 Biological diversity in metastatic neoplasms: origins and implications. Science 217: 998-1003.
16. Foley, M., and L. Tilley, 1997 Quinoline antimalarials: mechanisms of action and resistance. Int. J. Parasitol. 27: 231-240.
17. Fuchs, A., A. Joffe and J. Teugels, 2001 Expectation of the ratio of the sum of squares to the square of the sum: exact and asymptotic results. Theory Probab. Appl. 46: 243-255.
18. Geisler, J. P., S. L. Rose, H. E. Geisler, G. A. Miller and M. C. Wiemann, 2002 Drug resistance and tumor heterogeneity. CME J. Gynecol. Oncol. 7: 25-28.
19. Gerrish, P. J., and R. E. Lenski, 1998 The fate of competing beneficial mutations in an asexual population. Genetica 102-103: 127-144.
20. Haeno, H., Y. Iwasa and F. Michor, 2007 The evolution of two mutations during clonal expansion. Genetics 177: 2209-2221.
21. Haggarth, L., G. Auer, C. Busch, M. Norberg, M. Haggman et al., 2005 The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer. Scand. J. Urol. Nephrol. 39: 387-392.
22. Heppner, G. H., 1984 Tumor heterogeneity. Cancer Res. 44: 2259-2265.
23. Imhof, M., and C. Schlotterer, 2001 Fitness effects of advantageous mutations in evolving Escherichia coli populations. Proc. Natl. Acad. Sci. USA 98: 1113-1117.
24. Kansal, A. R., S. Torquato, E. A. Chiocca and T. S. Deisboeck, 2000 Emergence of a subpopulation in a computational model of tumor growth. J. Theor. Biol. 207: 431-441.
25. Komarova, N., 2006 Stochastic modeling of drug resistance in cancer. J. Theor. Biol. 239: 351-366.
26. Kunkel, T. A., and K. Bebenek, 2000 DNA replication fidelity. Annu. Rev. Biochem. 69: 497-529.
27. Lai, L. A., T. G. Paulson, X. Li, C. A. Sanchez, C. Maley et al., 2007 Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer 46: 532-542.
28. Lenski, R. E., and M. Travisano, 1994 Dynamics of adaptation and diversification: a 10,000-generation experiment with bacterial populations. Proc. Natl. Acad. Sci. USA 91: 6808-6814.
29. Lenski, R. E., M. R. Rose, S. C. Simpson and S. C. Tadler, 1991 Longterm experimental evolution in Escherichia coli. I. Adaptation and divergence during 2,000 generations. Am. Nat. 138: 1315-1341.
30. Logan, B. F., C. L. Mallows, S. O. Rice and L. A. Shepp, 1973 Limit distributions of self-normalized sums. Ann. Probab. 1: 788-809.
31. Loya, P., 2005 Dirichlet and fresnel integrals via integrated integration. Math. Mag. 78(1): 63-67.
32. Maley, C. C., P. C. Galipeau, J. C. Finley, V. J. Wongsurawat, X. Li et al., 2006 Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38: 468-473.
33. Merlo, L. M., J. W. Pepper, B. J. Reid and C. C. Maley, 2006 Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6: 924-935.
34. Michelson, S., K. Ito, H. T. Tran and J. T. Leith, 1989 Stochastic models for subpopulation emergence in heterogeneous tumors. Bull. Math. Biol. 51: 731-747.
35. Nguyen, H. N., B. U. Sevin, H. E. Averette, R. Ramos, P. Ganjei et al., 1993 Evidence of tumor heterogeneity in cervical cancers and lymph node metastases as determined by flow cytometry. Cancer 71: 2543-2550.
36. Nicolson, G. L., 1984 Generation of phenotypic diversity and progression in metastatic tumor cells. Cancer Metastasis Rev. 3: 25-42.
37. Oller, A. R., P. Rastogi, S. Morgenthaler and W. G. Thilly, 1989 A statistical model to estimate variance in long term-low dose mutation assays: testing of the model in a human lymphoblastoid mutation assay. Mutat. Res. 216: 149-161.
38. O'Sullivan, M., V. Budhraja, Y. Sadovsky and J. D. Pfeifer, 2005 Tumor heterogeneity affects the precision of microarray analysis. Diagn. Mol. Pathol. 14: 65-71.
39. Park, S. C., and J. Krug, 2007 Clonal interference in large populations. Proc. Natl. Acad. Sci. USA 104: 18135-18140.
40. Park, S. C., A. Simon and J. Krug, 2010 The speed of evolution in large asexual populations. J. Stat. Phys. 138: 381-410.
41. Resnick, S., 1987 Extreme Values, Regular Variation, and Point Processes. Springer-Verlag, Berlin/Heidelberg, Germany/New York
42. Ridout, M. S., 2008 Generating random numbers from a distribution specified by its laplace transform. Stat. Comput. 19: 439-450.
43. Rokyta, D. R., C. J. Beisel, P. Joyce, M. T. Ferris, C. L. Burch et al., 2008 Beneficial fitness effects are not exponential for two viruses. J. Mol. Evol. 67: 368-376.
44. Sanjuan, R., A. Moya and S. F. Elena, 2004 The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus. Proc. Natl. Acad. Sci. USA 101: 8396-8401.
45. Schweinsberg, J., 2008 The waiting time for m mutations. Electron. J. Probab. 13: 1442-1478.
46. Seshadri, R., R. J. Kutlaca, K. Trainor, C. Matthews and A. A. Morley, 1987 Mutation rate of normal and malignant human lymphocytes. Cancer Res. 47: 407-409.
47. Shao, Q. M., 1997 Self-normalized large deviations. Ann. Probab. 25: 285-328.
48. Shipitsin, M., L. L. Campbell, P. Argani, S. Weremowicz, N. Bloushtain-Qimron et al., 2007 Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273.
49. Wolman, S. R., 1986 Cytogenetic heterogeneity: its role in tumor evolution. Cancer Genet. Cytogenet. 19: 129-140.